ES2459877T3 - Combinación de nilotinib y clorambucil para el tratamiento de leucemia linfocítica crónica - Google Patents

Combinación de nilotinib y clorambucil para el tratamiento de leucemia linfocítica crónica Download PDF

Info

Publication number
ES2459877T3
ES2459877T3 ES08864891.0T ES08864891T ES2459877T3 ES 2459877 T3 ES2459877 T3 ES 2459877T3 ES 08864891 T ES08864891 T ES 08864891T ES 2459877 T3 ES2459877 T3 ES 2459877T3
Authority
ES
Spain
Prior art keywords
combination
nilotinib
clb
cll
chlorambucil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08864891.0T
Other languages
English (en)
Spanish (es)
Inventor
Raquel Silvia Aloyz
Lawrence Carl Panasci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2459877T3 publication Critical patent/ES2459877T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES08864891.0T 2007-12-21 2008-12-18 Combinación de nilotinib y clorambucil para el tratamiento de leucemia linfocítica crónica Active ES2459877T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15704 1998-01-29
US1570407P 2007-12-21 2007-12-21
PCT/US2008/087336 WO2009082662A1 (en) 2007-12-21 2008-12-18 Combination of nilotinib and a nitrogen mustard analogue for the treatment of chronic lymphocytic leukemia

Publications (1)

Publication Number Publication Date
ES2459877T3 true ES2459877T3 (es) 2014-05-12

Family

ID=40352369

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08864891.0T Active ES2459877T3 (es) 2007-12-21 2008-12-18 Combinación de nilotinib y clorambucil para el tratamiento de leucemia linfocítica crónica

Country Status (7)

Country Link
US (2) US20110028422A1 (enExample)
EP (1) EP2240172B1 (enExample)
JP (2) JP2011507880A (enExample)
ES (1) ES2459877T3 (enExample)
PL (1) PL2240172T3 (enExample)
PT (1) PT2240172E (enExample)
WO (1) WO2009082662A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2425830A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
CN106102722A (zh) * 2014-03-13 2016-11-09 V·沃道里斯 苯达莫司汀固体分散体和连续输液
US9777572B2 (en) * 2014-11-17 2017-10-03 Baker Hughes Incorporated Multi-probe reservoir sampling device

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3046301A (en) 1959-10-29 1962-07-24 Burroughs Wellcome Co Method of making chlorambucil
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
BR0316126A (pt) * 2002-11-12 2005-09-27 Jewish General Hospital Combinação de compostos para o tratamento de leucemia linfocìtica crÈnica
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida

Also Published As

Publication number Publication date
WO2009082662A1 (en) 2009-07-02
EP2240172A1 (en) 2010-10-20
JP2014177487A (ja) 2014-09-25
PL2240172T3 (pl) 2014-08-29
US20150051236A1 (en) 2015-02-19
PT2240172E (pt) 2014-05-28
EP2240172B1 (en) 2014-03-19
JP2011507880A (ja) 2011-03-10
US20110028422A1 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
JP2023515817A (ja) ダブラフェニブ、ｅｒｋ阻害剤及びｓｈｐ２阻害剤を含む三重の医薬品の組合せ
US8492383B2 (en) Combination of a nitrogen mustard analogue and imatinib for treatment of chronic lymphocytic leukemia
CN104023715B (zh) 激酶抑制剂的副作用降低剂
ES2459877T3 (es) Combinación de nilotinib y clorambucil para el tratamiento de leucemia linfocítica crónica
EP4297750A1 (en) Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis
US20090298791A1 (en) Combinations comprising epothilones and antimetabolites
JP2006508118A5 (enExample)
EP1496908B1 (en) Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
US20220409582A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
AU2006279781A1 (en) Combination of organic compounds
CN119836291A (zh) 包含bcl-2抑制剂的癌症组合疗法
TWI674094B (zh) 治療或緩解慢性骨髓性白血病用之醫藥組合物
AU2007200677B2 (en) Combinations comprising epothilones and anti-metabolites
US20190054085A1 (en) Composition and method for treatment of depression and psychosis in humans
PT1909837E (pt) COMPOSIÎES PARA O TRATAMENTO DA MASTOCITOSE SISTéMICA
CN101198253A (zh) 治疗癌症的组合、方法和组合物